Bacterial (Pyogenic) Meningitis ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Bacterial (Pyogenic) Meningitis ' Pipeline Review, H2 2012
Published on December 2012

Report Summary


Summary

Global Markets Direct's, 'Bacterial (Pyogenic) Meningitis - Pipeline Review, H2 2012', provides an overview of the indication's
therapeutic pipeline. This report provides information on the therapeutic development for Bacterial (Pyogenic) Meningitis, complete
with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the
therapeutic development for Bacterial (Pyogenic) Meningitis. Bacterial (Pyogenic) Meningitis - Pipeline Review, Half Year is built using
data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial (Pyogenic) Meningitis.
- A review of the Bacterial (Pyogenic) Meningitis products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacterial (Pyogenic) Meningitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacterial (Pyogenic) Meningitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacterial (Pyogenic) Meningitis pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Bacterial (Pyogenic) Meningitis ' Pipeline Review, H2 2012 (From Slideshare) Page 1/7


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bacterial (Pyogenic) Meningitis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Bacterial (Pyogenic) Meningitis 8
Bacterial (Pyogenic) Meningitis Therapeutics under Development by Companies 10
Bacterial (Pyogenic) Meningitis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Pre-Clinical Stage Products 14
Bacterial (Pyogenic) Meningitis Therapeutics ' Products under Development by Companies 15
Bacterial (Pyogenic) Meningitis Therapeutics ' Products under Investigation by Universities/Institutes 16
Companies Involved in Bacterial (Pyogenic) Meningitis Therapeutics Development 17
Novartis AG 17
Pfizer Inc. 18
GlycoVaxyn AG 19
Sinovac Biotech Ltd. 20
China National Pharmaceutical Group Corporation 21
Bacterial (Pyogenic) Meningitis ' Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Meningitis Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Quadrivalent Meningococcal Conjugate Vaccine (MCV4) - Drug Profile 29
R&D Progress 29
MnB rLP2086 - Drug Profile 31
R&D Progress 31
acetaminophen - Drug Profile 33



R&D Progress 33
Glycerol + Paracetamol - Drug Profile 34
R&D Progress 34
Bexsero - Drug Profile 35
R&D Progress 35
Bexsero - Drug Profile 37
R&D Progress 37
Amphotericin B + Fluconazole - Drug Profile 39
R&D Progress 39
dexamethasone beloxil - Drug Profile 40
R&D Progress 40
Meningococcal Group B Meningitis Vaccine - Drug Profile 41
R&D Progress 41
rLP2086 + Repevax - Drug Profile 42
R&D Progress 42
Conjugated Meningococcal C Vaccine - Drug Profile 44
R&D Progress 44
Pneumococcal Vaccine - Drug Profile 46
R&D Progress 46
Pneumococcal Vaccine - Drug Profile 47
R&D Progress 47
Vi-CRM197 PCMV - Drug Profile 48
R&D Progress 48
Bacterial (Pyogenic) Meningitis Therapeutics ' Drug Profile Updates 49



Bacterial (Pyogenic) Meningitis Therapeutics - Dormant Products 52
Bacterial (Pyogenic) Meningitis ' Product Development Milestones 53
Featured News & Press Releases 53
Feb 07, 2012: Novartis's Pivotal Study Confirms Potential Of Candidate Vaccine Bexsero To Help Protect Infants Against Devastating
Meningococcal Serogroup B Disease 53
Jun 09, 2011: Novartis's Bexsero Shows Significant Potential In Providing Broad Coverage Against Meningococcal Serogroup B
Infections 54
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables

Number of Products Under Development for Bacterial (Pyogenic) Meningitis, H2 2012 8
Products under Development for Bacterial (Pyogenic) Meningitis ' Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Novartis AG, H2 2012 17
Pfizer Inc., H2 2012 18
GlycoVaxyn AG, H2 2012 19
Sinovac Biotech Ltd., H2 2012 20
China National Pharmaceutical Group Corporation, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Bacterial (Pyogenic) Meningitis Therapeutics ' Drug Profile Updates 49
Bacterial (Pyogenic) Meningitis Therapeutics ' Dormant Products 52

List of Figures

Number of Products under Development for Bacterial (Pyogenic) Meningitis, H2 2012 8
Products under Development for Bacterial (Pyogenic) Meningitis ' Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10



Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Bacterial (Pyogenic) Meningitis ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Bacterial (Pyogenic) Meningitis ' Pipeline Review, H2 2012